参考文献

[1]Ginsberg F.β-blockers;more good news?Crit Care Med,2012,40(10):2901-2902.

[2]Sanfilippo F,Santonocito C,foex P.Use of beta-blockers in non-cardiac surgery:an open debate.Minerva Anestesiol,2014,80(4):482-494.

[3]Duan EH,Oczkowski SJ,Belley-Cote E,et al.β-Blockers in sepsis:protocol for a systematic review and metaanalysis of randomised control trials.BMJOpen,2016,6(6):e012466.

[4]Chacko CJ,Gopal S.Systematic review of use of β-blockers in sepsis.J Anaesthesiol Clin Pharmacol,2015,31(4):460-465.

[5]Hamzaoui O,Teboul JL.The role of beta-blockers in septic patients.Minerva Anestesiol,2015,81(3):312-319.

[6]Sanfilippo F,Santonocito C,Morelli A,et al.Beta-blocker use in severe sepsis and septic shock:a systematic review.Curr Med Res Opin,2015,31(10):1817-1825.

[7]Kargin F,Takir HB,Salturk C,et al.The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit.Multidiscip Respir Med,2014,9(1):8.

[8]Mac Sweeney R,Devereaux PJ,McAuley DF.Beta 2 antagonism in acute respiratory failure.Crit Care,2010,14(6):1012.

[9]Noveanu M,Breidthardt T,Reichlin T,et al.Effect of oralβ-blocker on short and long-term mortality in patientswith acute respiratory failure:results from the BASEL-II-ICU study.Crit Care,2010,14(6):R198.

[10]Silverman EK,Crapo J,Dransfield MT.β-Blockers are associated with a reduction in COPD exacerbations.Thorax,2016,71(1):8-14.

[11]Loftus TJ,Efron PA,Moldawer LL,et al.β-Blockade use for Traumatic Injuries and Immunomodulation:A Review of Proposed Mechanisms and Clinical Evidence.Shock,2016,46(4):341-351.

[12]Ko A,Harada MY,Barmparas G,et al.Early propranolol after traumatic brain injury is associated with lower mortality.JTrauma Acute Care Surg,2016,80(4):637-642.

[13]Zangbar B,Khalil M,Rhee P,et al.Metoprolol improves survival in severe traumatic brain injury independent of heart rate control.JSurg Res,2016,200(2):586-592.

[14]Murry JS,Hoang DM,Barmparas G,et al.Prospective evaluation of early propranolol after traumatic brain injury.JSurg Res,2016,200(1):221-226.

[15]Alali AS,McCredie VA,Golan E,et al.Beta blockers for acute traumatic brain injury:a systematic review and meta-analysis.Neurocrit Care,2014,20(3):514-523.

[16]De Montmollin E,Aboab J,Mansart A,et al.Bench-to-bedside review:Beta-adrenergic modulation in sepsis.Crit Care,2009,13(5):230.

[17]Stoelting RK,Hilller SC.Alpha and beta-adrenergic receptor antagonists.In:Pharmacology&Physiology in Anesthetic Practice.4th ed.Philadelphia:Lippincott,Williams&Wilkins;2006.p.321-327.

[18]Morelli A,Ertmer C,Westphal M,etal.Effectof heart rate controlwith esmolol on hemodynamic and clinical outcomes in patients with septic shock:a randomized clinical trial.JAMA,2013,310(6):1683-1691.

[19]Singer M,Deutschman CS,Seymour CW,et al.The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3).JAMA,2016,315(8):801-810.

[20]Shankar-Hari M,Phillips GS,Levy ML,etal.Developing a New Definition and Assessing New Clinical Criteria for Septic Shock:For the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3).JAMA,2016,315(8):775-787.

[21]Seymour CW,Liu VX,Iwashyna TJ,et al.Assessment of Clinical Criteria for Sepsis:For the Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3).JAMA,2016,315(8):762-774.

[22]Abraham E.New Definitions for Sepsis and Septic Shock:Continuing Evolution but With Much Still to Be Done.JAMA,2016,315(8):757-759.

[23]Jacob JA.New Sepsis Diagnostic Guidelines Shift Focus to Organ Dysfunction.JAMA.2016,315(8):739-740.

[24]Martin GS.Sepsis,severe sepsis and septic shock:changes in incidence,pathogens and outcomes.Expert Rev Anti Infect Ther,2012,10(6):701-706.

[25]Dellinger RP,Levy MM,Rhodes A,et al.Surviving sepsis campaign:international guidelines for management of severe sepsis and septic shock:2012.Crit Care Med,2013,41(2):580-637.

[26]Perner A,Gordon AC,De Backer D,et al.Sepsis:frontiers in diagnosis,resuscitation and antibiotic therapy.Intensive Care Med,2016,42(12):1958-1969.

[27]McConnell KW,Coopersmith CM.Pathophysiology of septic shock:from bench to bedside.Presse Med,2016,45(4 pt2):e93-98.

[28]Rudiger A.Beta-block the septic heart.Crit Care Med,2010,38(10 suppl):S608-S612.

[29]Schmittinger CA,Torgersen C,Luckner C,et al.Adverse cardiac events during catecholamine vasopressor therapy:a prospective observational study.Intensive Care Med,2012,38(6):950-958.

[30]Fenton KE,Parker MM.Cardiac function and dysfunction in sepsis.Clin Chest Med,2016,37(2):289-298.

[31]Latini R,Caironi P,Masson S.Cardiac dysfunction and circulating cardiac markers during sepsis.Minerva Anestesiol,2016,82(6):697-710.

[32]Kakihana Y,Ito T,Nakahara M,et al.Sepsis-induced myocardial dysfunction:pathophysiology and management.J Intensive Care,2016,4:22.

[33]Lv X,Wang H.Pathophysiology of sepsis-induced myocardial dysfunction.Mil Med Res,2016,3:30.

[34]Macchia A,Romero M,Comignani PD,etal.Previous prescription ofbeta-blockers is associated with reduced mortality among patients hospitalized in intensive care units for sepsis.Crit Care Med,2012,40(10):2768-2772.

[35]Morelli A,Ertmer C,Westphal M,et al.Effectof heart rate controlwith esmolol on hemodynamic and clinical outcomes in patients with septic shock:a randomized clinical trial.JAMA,2013,310(16):1683-1691.

[36]曾文新,江稳强,黄澄,等.β1-受体阻滞剂对感染性休克患者血流动力学和炎症反应的影响.中国急救医学,2016,36(5):388-392.

[37]Pinsky MR.Is there a role forβ-blockade in septic shock?.JAMA,2013,310(16):1677-1678.

[38]胡涛,李树生.β受体阻滞剂在脓毒症中的临床应用.临床内科杂志,2015,32(6):367-369.

[39]刘军,李维勤.β受体阻滞剂在脓毒症中的作用研究进展.肠外与肠内营养,2014,21(4):244-246.

[40]Schmittinger CA,Dnnser MW,Togersen C,et al.Histologic pathologies of themyocardium in septic shock:a prospective obsercational study.Shock,2013,39(4):329-335.

[41]Parker MM,Shelhamer JH,Natanson C,et al.Serial cardiovascular variables in survivors and nonsurvivors of human septic shock:heart rate as an early predictor of prognosis.Crit Care Med,1987,15(10):923-929.

[42]Romero-Bermejo FJ,Ruiz-Bailen M,Gil-Cebrian J,et al.Sepsis-induced cardiomyopathy.Curr Cardiol Rev,2011,7(3):163-183.

[43]Noveanu M,Breidthardt T,Reichlin T,et al.Effect of oral beta-blocker on short and long-term mortality in patients with acute respiratory failure:results from the BASEL-II-ICU study.Crit Care,2010,14:R198.

[44]Sweeney RM,Devereaux PJ,McAuley DF.Beta 2 antagonism in acute respiratory failure.Crit Care,2010,14:1012-.

[45]Ni Y,Shi G,Wan H.Use of cardioselectiveβ-blockers in patients with chronic obstructive pulmonary disease:a meta-analysis of randomized,placebo-controlled,blinded trials.J Int Med Res,2012,40(6):2051-2065.

[46]Albouaini K,Andron M,Alahmar A,et al.Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions.Int JChron Obstruct Pulmon Dis,2007,2(4):535-540.

[47]Salpeter SR,Ormiston TM,Salpeter EE,et al.Cardioselective beta-blockers for chronic obstructive pulmonary disease:ameta-analysis.Respir Med,2003,97(10):1094-1101.

[48]Campo G,Pavasini R,Biscaglia S,et al.Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease,Eur Heart J Cardiovasc Pharmacother.2015 Jul;1(3):205-211.

[49]Bhatt SP,Wells JM,Kinney GL,et al.β-blockers are associated with a reduction in COPD exacerbations.Thorax,2016,71(1):8-14.

[50]van derWoude HJ,Zaagsma J,Postma DS,et al.Detrimental effects of beta-blockers in COPD:a concern for nonselective beta-blockers.Chest,2005,127(3):818-824.

[51]van der Jagt M,van der Miranda DR.Beta-blockers in intensive care medicine:potential benefit in acute brain injury and acute respiratory distress syndrome.Recent Pat Cardiovasc Drug Discov,2012,7(2):141-151.

[52]Kargin F,Takir HB,Salturk C,et al.The safety of beta-blocker use in chronic obstructive pulmonary disease patients with respiratory failure in the intensive care unit.Multidiscip Respir Med,2014;9(1):8.

[53]Hagiwara S,Iwasaka H,Maeda H,et al.Landiolol,an ultrashort-acting beta1-adrenoceptor antagonist,has protective effects in an LPS-induced systemic inflammation model.Shock.2009,31(5):515-520.

[54]Aboab J,Sebille V,Jourdain M,et al.Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigswith hypodynamic endotoxin shock.Intensive Care Med,2011,37(8):1344-1351.

[55]Meyer KS.Understanding paroxysmal sympathetic hyperactivity after traumatic brain injury.Surg Neurol Int,2014,5(Suppl 13):S490-S492.

[56]Woolf PD,Hamill RW,Lee LA,et al.The predictive value of catecholamines in assessing outcome in traumatic brain injury.JNeurosurg,1987,66(6):875-882.

[57]Goldstein B,Toweill D,Lai S,et al.Uncoupling of the autonomic and cardiovascular systems in acute brain injury.Am JPhysiol,1998,275(4 Pt2):R1287-1292.

[58]Hortnagl H,Hammerle AF,Hackl JM,et al.The activity of the sympathetic nervous system following severe head injury.Intensive Care Med,1980,6(3):169-170.

[59]Bruder N,Rabinstein A.Cardiovascular and pulmonary complications of aneurysmal subarachnoid hemorrhage.Neurocrit Care,2011,15(2):257-269.

[60]Lewis PR,Dunne CE,Thompson KA,et al.Attenuation of cardiovascular stress with sympatholytics does not improve survival in patientswith severe isolated traumatic brain injury.J Trauma Acute Care Surg,2016,80(4):643-647.

[61]Samuel S,Allison TA,Lee K,et al.Pharmacologic Management of Paroxysmal Sympathetic Hyperactivity After Brain Injury.J Neurosci Nurs,2016,48(2):82-89.

[62]Ker K,Perel P,Blackhall K.Beta-2 receptor antagonists for traumatic brain injury:a systematic review of controlled trials in animalmodels.CNSNeurosci Ther,2009,15(1):52-64.

[63]Greendyke RM,Kanter DR,Schuster DB,et al.Propranolol treatmentof assaultive patientswith organic brain disease.A double-blind crossover,placebo-controlled study.JNerv Ment Dis,1986,174(5):290-294.

[64]Feibel JH,Baldwin CA,Joynt RJ.Catecholamine-associated refractory hypertension following acute intracranial hemorrhage:controlwith propranolol.Ann Neurol,1981,9(4):340-343.

[65]Alali AS,McCredie VA,Golan E,et al.Beta blockers for acute traumatic brain injury:A systematic review and meta-analysis.Neurocrit Care,2014,20(3):514-523.

[66]Schroeppel TJ,Fischer PE,Zarzaur BL,et al.Beta-adrenergic blockade and traumatic brain injury:protective?JTrauma,2010,69(4):776-782.

[67]杨帅鼎,王子岩,万有栋,等.β-受体阻滞剂对创伤性颅脑损伤患者院内病死率的影响.中国实用神经疾病杂志,2016,19(4):79-82.